Summary

Other Scenarios:

Buyer: Schering AG (ADR) (SHR) Last Price: 120.31 Market Cap.: 22.96B
Target: Barr Pharmaceuticals, Inc. (BRL) Last Price: 50.54 Market Cap.: 5.38B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 870
Biopharmaceuticals 329
Medical Devices 247

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 79)
  • Cathepsin S Inhibitor
  • Berlex Betapace/Betapace AF (Sotalol Hydrochloride)
  • Berlex Betaseron (Interferon Beta-1b)
  • Berlex AGT-MI (FGF-4 Gene Therapy)
Target (Total: 115)
  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  • Fexofenadine/Pseudoephedrine
Buyer
  • Gadofluorine Derivative
  • Berlex Vasovist (Gadofosveset)
  • Medrad Mark V ProVis Injection System
  • Medrad Mark Series
Target
  • ViaSpan (Belzer UW)
  • ParaGard T 380A

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 15)
  • Advanced Magnetics, Inc. (AMAG)
  • Biogen Idec Inc. (BIIB)
  • Serono S.A. (ADR) (SRA)
  • Millennium Pharmaceuticals, Inc. (MLNM)
Target (Total: 2)
  • Mack-Cali Realty Corp. (CLI)
  • Common Sense Ltd.
Buyer (Total: 5)
  • Millennium Pharmaceuticals, Inc. (MLNM)
  • Cotherix, Inc (CTRX)
  • Sonus Pharmaceuticals, Inc. (SNUS)
  • Favrille, Inc. (FVRL)
Target (Total: 7)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • AmerisourceBergen Corp. (ABC)
  • Walgreen Company (WAG)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 23,098 2,040
Revenue Per Employee 308,724.3 653,496.3
Total Revenue 1,779.7 332.4
Total Expenses 1,566.3 219.2
Other Revenue 0.0 31.9
Cost of Revenue 415.4 81.7
SG&A Expense 738.0 97.5
Research & Development 310.0 40.0
Other Operating Expense 102.9 0.0
Operating Income 213.4 113.2
Unusual Income 0.0 0.0
LT Debt to Capital 5.88 0.42
Fwd P/E n/a 15.38
Fwd P/Rev n/a 3.70
Book Value 4,297.3 1,764.0
Curr Portion of LTD/Cap Lease 30.1 8.5

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals

Business Description

Buyer

Schering AG is a global research-based company engaged in the discovery, development, manufacture, marketing and sale of pharmaceutical products. The Company operates eight research and development centers in Europe, the United States and Japan, produce products in facilities located in Europe, the United States, Latin America and Asia, and markets and sells its products in over 100 countries worldwide. Its research and development efforts are primarily concentrated on the commercialization of technologies for unmet medical needs in its four core business areas: Gynecology & Andrology, Diagnostic Imaging, Specialized Therapeutics and Oncology. The Company derived approximately 38% of its net sales, during the year ended December 31, 2005, from sales of four key products: Betaferon, sold in the United States and Canada under the Betaseron trademark (16% of net sales); Yasmin (11%); Magnevist (6%), and Ultravist (5%). Bayer AG gained control of a total of 88% of the Company in June 2006.

Target

Barr Pharmaceuticals, Inc. is primarily a holding company. The Company's subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceutical products, respectively. It operates in two business segments. In the generic pharmaceutical segment, it manufactures and distributes approximately 150 different dosage forms and strengths of approximately 75 different generic pharmaceutical products, including 22 oral contraceptive products that represent the largest category of its generic product portfolio. In the proprietary pharmaceutical segment, the Company manufactures and distributes 19 proprietary pharmaceutical products, largely concentrated in the women's healthcare therapeutic category. These products include SEASONALE and SEASONIQUE extended-cycle oral contraceptive products, and Cenestin (synthetic conjugated estrogens, A) and ENJUVIA (synthetic conjugated estrogens, B) line of hormone therapy products.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 76.83 73.53
Operating Margin % 15.61 35.46
Quick Ratio 1.76 4.09
Current Ratio 2.31 5.08
Coverage Ratio 0.02 0.04
Total Assets 7,378.4 2,068.4
Return on Equity % 17.64 17.35
Return on Assets % 10.27 14.79
Cash+ ST Inv. Per Share 8 6.97
Total Debt 298.7 15.9
Total Debt to Equity % 6.95 0.9
Total Debt to Tangible Equity % 8.61 1.28
Debt to Asset % 4.05 0.77

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
  
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
  
Neurology
The Neurology Subsector includes medical devices that diagnose, monitor and treat neurological disorders.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes medical devices that diagnose and treat female reproductive diseases; devices used to care for women during pregnancy, childbirth, and the post-partum period are also included in this sector.
  
Oncology
The Oncology Subsector includes medical devices that detect and treat cancers.
  
Radiology
The Radiology Subsector includes medical devices that generate images of internal physiology.
  
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
  
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of allergic reactions in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Upper Respiratory  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Target Products:

  • Diphenhydramine Hydrochloride
  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Target Products:

  • Fexofenadine/Pseudoephedrine
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.

Target Products:

  • Triamcinolone Acetonide Nasal Spray
  
Cardiovascular System
Heart Disorders
Arrhythmia
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Berlex Betapace/Betapace AF (Sotalol Hydrochloride)
  
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.

Target Products:

  • Flecainide Acetate
  
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.

Target Products:

  • Amiodarone Hydrochloride
  
Heart Failure (HF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.

Target Products:

  • Triamterene/Hydrochlorothiazide
  • Amiloride Hydrochloride/Hydrochlorothiazide
  
Myocardial Infarction (MI)  
Free Fatty Acid Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niaspan (Niacin)
  • Niacin Extended-Release
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Berlex Betaseron (Interferon Beta-1b)
  • Berlex AGT-MI (FGF-4 Gene Therapy)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Vascular Disorders
Atherosclerosis  
Free Fatty Acid Inhibitors
Therapeutics that treat the narrowing or hardening of arteries by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niaspan (Niacin)
  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Target Products:

  • Warfarin Sodium
  
Hypertension  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Target Products:

  • Duramed Zebeta (Bisoprolol Fumarate)
  
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Target Products:

  • Duramed Ziac (Bisoprolol Fumarate/Hydrochlorothiazide)
  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.

Target Products:

  • Amiloride Hydrochloride/Hydrochlorothiazide
  • Triamterene/Hydrochlorothiazide
  
Peripheral Vascular Disease  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat arterial obstruction outside of the heart by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
Thromboembolism
Anticoagulating Agents (Anticoagulants)
Platelet Aggregation Inhibitors  
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.

Target Products:

  • Dipyridamole
  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Berlex Refludan (Lepirudin)

Target Products:

  • Warfarin Sodium
Dermatology
Acne
Rosacea  
Azelaic Acid
Therapeutics that treat and prevent rosacea caused by bacteria.

Buyer Products:

  • Berlex Finacea (Azelaic Acid)
  
Vulgaris  
Antibacterial Agents  
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.

Target Products:

  • Erythromycin
  
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Tetracycline Hydrochloride
  
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.

Target Products:

  • Claravis (Isotretinoin)
  
Lesion/Scaling Disorders  
Chronic Urticaria  
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.

Target Products:

  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Fexofenadine Hydrochloride
  
Pruritus  
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.

Target Products:

  • Hydroxyzine Pamoate
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • CRA-028129 (Cathepsin S Inhibitor)
  • Berlex Tisocalcitate (Calcitriol Analog)
  
Digestive System
Gastrointestinal Tract Disorders
Gastroesophageal Disorders  
Nausea/Vomiting  
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.

Target Products:

  • Prochlorperazine Maleate
  
Intestinal Disorders  
Inflammatory Bowel Disease (IBD)  
Crohn`s Disease  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Stomatognathic Disorders  
Mucositis  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat mucositis by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Target Products:

  • Triamterene/Hydrochlorothiazide
  
Endocrinology/Metabolism
Adrenal Gland Disorders  
Adrenocortical Insufficiency  
Synthetic Adrenocortical Steroids
Therapeutics that treat Adrenocortical Insufficiency by acting on the distal tubules of the kidney to enhance the reabsorption of sodium ions and to increase the urinary excretion of both potassium and hydrogen ions.

Target Products:

  • Fludrocortisone Acetate
  
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Target Products:

  • Desmopressin Acetate
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.

Target Products:

  • Metformin Hydrochloride Extended-Release
  • Metformin Hydrochloride
  
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Target Products:

  • Acetohexamide
  
General Hormone Treatments  
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.

Target Products:

  • Estropipate
  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
  • Estradiol
  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.

Target Products:

  • Methylprednisolone
  
Intermediary Metabolism Disorders  
Gout  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Target Products:

  • Sulfinpyrazone
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.

Target Products:

  • Sulfinpyrazone
  
Hypercholesterolemia  
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niaspan (Niacin)
  • Niacin Extended-Release
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat elevated cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
Hyperlipidemia  
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Target Products:

  • Niaspan (Niacin)
  • Niacin Extended-Release
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
Reproductive Disorders
Amenorrhea  
Progestins
Female sex hormone necessary for the development of the female reproductive system.

Target Products:

  • Medroxyprogesterone
  • Duramed Aygestin (Norethindrone Acetate)
  
Hypoestrogenism  
Hormonal Treatments  
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)
  
Hypogonadism  
Female  
Hormonal Treatments  
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)
  
Menopause
Estrogens
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
  • Estradiol
  • Estropipate
  • Duramed Enjuvia (Synthetic Conjugated Estrogens)
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.

Buyer Products:

  • Berlex Climodien 1/2 (Estradiolvalerate/Dienogest)
  • Berlex Climara Pro (Levonorgestrel/Estradiol Transdermal)
  • Berlex Angeliq (Drospirenone/Estradiol)

Target Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
Progestins
Therapeutics that are female sex hormones.

Buyer Products:

  • Berlex Levonorgestrel Intrauterine System

Target Products:

  • Medroxyprogesterone
Hematology
Hemophilia  
Hemophilia A  
Antidiuretic Agents
Therapeutics that treat prevent the loss of water in the urine.

Target Products:

  • Desmopressin Acetate
  
Red Blood Cell (RBC) Disorders  
Anemia  
Folic Acid Derivatives
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by folic acid deficiency.

Target Products:

  • Leucovorin
  
Serum Factor Disorders  
Hypercholesterolemia  
Free Fatty Acid Inhibitors
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue.

Target Products:

  • Niacin Extended-Release
  • Niaspan (Niacin)
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the abnormally high concentrations of cholesterol by inhibiting the release of fatty acids from adipose tissue and blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
Hyperlipidemia  
Free Fatty Acid Inhibitors
Therapeutics that inhibit the release of fatty acids from adipose tissue.

Target Products:

  • Niacin Extended-Release
  
Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hyperlipidemia by inhibiting the release of free fatty acid from adipose tissues as well as blocking cholesterol synthesis by binding a key enzyme in the synthesis process.

Target Products:

  • Advicor (Niacin/Lovastatin)
  
Hyperuricemia  
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.

Target Products:

  • Sulfinpyrazone
  
Hypokalemia  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.

Target Products:

  • Triamterene/Hydrochlorothiazide
  
Thrombocyte (Platelet) Disorders  
Thrombocythemia  
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.

Target Products:

  • Anagrelide Hydrochloride
  
White Blood Cell (WBC) Disorders  
Neutropenia  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Immunology
Autoimmune Disorders
Arthritis  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Target Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Target Products:

  • Leflunomide
  
Inflammatory Bowel Disease (IBD)  
Crohn`s Disease  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat Crohn's Disease by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Multiple Sclerosis (MS)  
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that downregulates the antibody response of the immune system.

Buyer Products:

  • Berlex Betaseron (Interferon Beta-1b) For SC Injection
  • Berlex Betaseron (Interferon Beta-1b)
  
Psoriasis  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by blocking the action of the dihydrofolate enzyme.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Immune Deficiency Disorders  
Hereditary Angioedema  
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.

Target Products:

  • Danazol
  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Target Products:

  • Didanosine Delayed Release
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Berlex Tisocalcitate (Calcitriol Analog)
  • Berlex Campath (Alemtuzumab)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.

Target Products:

  • Erythromycin
  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.

Target Products:

  • Demeclocycline Hydrochloride
  • Tetracycline Hydrochloride
  
Narrow Spectrum  
Otolaryngology (Ear/Nose/Throat)  
Otitis Media  
Macrolides/Sulfonamides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis and by inhibiting folic acid synthesis.

Target Products:

  • Erythromycin Ethylsuccinate/Sulfisoxazole
  
Respiratory System  
Pneumonia  
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Tuberculosis  
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.

Target Products:

  • Ethambutol Hydrochloride
  • Isoniazid
  
Urology  
Prostatitis  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Target Products:

  • Ciprofloxacin
  
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Azoles  
Triazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Target Products:

  • Fluconazole
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Target Products:

  • Adenovirus Vaccine
  
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Malaria  
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.

Target Products:

  • Mefloquine Hydrochloride
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Human Papilloma Virus Vaccine
  
Viral  
RNA Viruses  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Target Products:

  • Didanosine Delayed Release
  
Musculoskeletal System
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Skeletal Disorders
Bone Disorders
Osteoporosis
Hormonal Treatments
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Berlex Menostar (Estradiol)
  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Estropipate
  • Estradiol
Estrogens/Progestins
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.

Buyer Products:

  • Berlex Climara Pro (Levonorgestrel/Estradiol Transdermal)

Target Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  • Nevis (Norethindrone Acetate/Ethinyl Estradiol)
Joint Disorders  
Gouty Arthritis  
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.

Target Products:

  • Sulfinpyrazone
  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.

Target Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Target Products:

  • Leflunomide
  
Neurology
Neurological Disorders  
Alzheimer`s Disease  
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.

Target Products:

  • Galantamine Hydrobromide
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Target Products:

  • Zonisamide
  • Topiramate
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Target Products:

  • Topiramate
  
Simple  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Target Products:

  • Zonisamide
  • Topiramate
  
Monotherapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Target Products:

  • Topiramate
  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Akinetic Pattern  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Myoclonic  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.

Target Products:

  • Clonazepam ODT
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.

Target Products:

  • Clonazepam ODT
  
Tonic-Clonic (Grand Mal)  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Target Products:

  • Topiramate
  
Headaches  
Tension Type  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat tension type headaches by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Target Products:

  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  • Isometheptene/Dichloralphenazone/Acetaminophen
  
Vascular (Migraine)  
Acute Treatments  
Analgesics/Sedatives/Vasoconstrictive Agents
Therapeutics that treat migraine by inhibiting the action of prostaglandins, constricting blood vessels in the brain thus reducing the pulsing action of blood in the cerebral arteries, and exerting a mild sedative effect.

Target Products:

  • Isometheptene/Dichloralphenazone/Acetaminophen
  • Duradrin (Isometheptene/Dichloralphenazone/Acetaminophen)
  
Neuromuscular Disorders
Multiple Sclerosis (MS)  
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that down regulates the antibody response of the immune system.

Buyer Products:

  • Berlex Betaseron (Interferon Beta-1b)
  • Berlex Betaseron (Interferon Beta-1b) For SC Injection
  
Myasthenia Gravis (MG)  
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.

Target Products:

  • Pyridostigmine Bromide
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Berlex Spheramine
  • Berlex Campath (Alemtuzumab)
  
Psychiatric Disorders
Anxiety  
Generalized Anxiety Disorder (GAD)  
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.

Target Products:

  • Hydroxyzine Pamoate
  
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.

Target Products:

  • Prochlorperazine Maleate
  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Alprazolam Extended Release
  • Diazepam
  • Chlordiazepoxide Hydrochloride
  
Obsessive Compulsive Disorder (OCD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.

Target Products:

  • Fluvoxamine Maleate
  • Fluoxetine Hydrochloride
  
Panic Disorder  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Clonazepam ODT
  • Alprazolam Extended Release
  
Childhood/Adolescent Disorders  
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD)  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.

Target Products:

  • Dextroamphetamine Sulfate Extended Release
  • Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate And Amphetamine Sulfate Tablets
  
Enuresis (Bedwetting)  
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.

Target Products:

  • Desmopressin Acetate
  
Eating Disorders  
Bulimia  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.

Target Products:

  • Fluoxetine Hydrochloride
  
Mood Disorders
Bipolar Disorders (Manic Depressive Disorders)  
Lithium-Based Agents
Therapeutics that treat bipolar disorders by decreasing the concentrations of neurotransmitters.

Target Products:

  • Lithium Carbonate Extended Release
  
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.

Target Products:

  • Risperidone
  • Olanzapine
  
Depression  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.

Target Products:

  • Fluoxetine Hydrochloride
  • Trazodone Hydrochloride
  
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.

Target Products:

  • Mirtazapine
  
Premenstrual Dysphoric Disorders  
Estrogens/Progestins
Therapeutics that treat premenstrual dysphoric disorders by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus.

Buyer Products:

  • Berlex YAZ (Drospirenone/Ethinyl Estradiol)
  
Schizophrenia  
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.

Target Products:

  • Prochlorperazine Maleate
  
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.

Target Products:

  • Olanzapine
  • Risperidone
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Target Products:

  • Diazepam
  
Narcolepsy  
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.

Target Products:

  • Modafinil
  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hronic and sudden daytime sleepiness.

Target Products:

  • Dextroamphetamine Sulfate Extended Release
  
Obstetrics/Gynecology
Child Birth/Pregnancy
Prevention (Contraception)
Contraceptives (Birth Control)
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Target Products:

  • Kelnor (Ethynodiol Diacetate/Ethinyl Estradiol)
  
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.

Buyer Products:

  • Berlex Tri-Levlen 21/Tri-Levlen 28 (Levonorgestrel/Ethinyl Estradiol Tablets)
  • Berlex Yasmin (Drospirenone/Ethinyl Estradiol)
  • Berlex E2/DNG Pill (Estradivalerate/Dienogest)
  • Berlex FC Patch (Gestodene/Ethinyl Estradiol)
  • Berlex YAZ (Drospirenone/Ethinyl Estradiol)
  • Berlex Levlen 21/Levlen 28 (Levonorgestrel/Ethinyl Estradiol Tablets)
  • Berlex Levlite (Levonorgestrel/Ethinyl Estradiol Tablets)

Target Products:

  • Velivet (Desogestrel/Ethinyl Estradiol)
  • Portia (Levonorgestrel/Ethinyl Estradiol)
  • Enpresse (Levonorgestrel/Ethinyl Estradiol)
  • Kariva (Desogestrel/Ethinyl Estradiol)
  • Lessina (Levonorgestrel/Ethinyl Estradiol)
  • Nortrel (Ethinyl Estradiol/Norethindrone) 7/7/7
  • Duramed Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Sprintec/Tri-Sprintec (Norgestimate/Ethinyl Estradiol)
  • Aviane 28 (Levonorgestrel/Ethinyl Estradiol)
  • Cryselle (Norgestrel/Ethinyl Estradiol)
  • Duramed Nordette Tablets (Levonorgestrel/Ethinyl Estradiol)
  • Seasonique Extended Release (Levonorgestrel/Ethinyl Estradiol)
  • Loestrin Fe (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Junel (Norethindrone Acetate, Ethinyl Estradiol, Ferrous Fumarate)
  • Drospirenone/Ethinyl Estradiol
  • Lo Seasonale (Levonorgestrel/Ethinyl Estradiol)
  • Apri (Desogestrel/Ethinyl Estradiol)
  • Mircette (Desogestrel Ethinyl Estradiol)
  • Aranelle (Norethindrone/Ethinyl Estradiol)
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system

Buyer Products:

  • Berlex Mirena (Levonorgestrel-Releasing Intrauterine Device)

Target Products:

  • Plan B OTC (Levonorgestrel)
  • Errin (Norethindrone)
  • Norethindrone Acetate
  • Camila (Norethindrone)
  • Plan B Prescription (Levonorgestrel)
Female Genital Disorders
Endometriosis
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.

Target Products:

  • Danazol
  
Gonadotropin Releasing Hormone (GnRH) Agonists
Therapeutics that treat endometriosis by suppressing the secretion of luteinizing hormone which results in decreased testosterone concentrations.

Buyer Products:

  • Berlex Endometrion (Dienogest)
  
Ovarian
Hypogonadism
Hormonal Treatments
Estrogens
These are female sex hormones.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Estropipate
  • Estradiol
Vulvovaginal
Atrophy
Hormonal Treatments
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.

Buyer Products:

  • Berlex Climara (Estradiol Transdermal System)

Target Products:

  • Bijuva Cream (Synthetic Conjugated Estrogens, A)
  • Estradiol
  • Estropipate
  • Duramed Cenestin (Synthetic Conjugated Estrogens, A)
Estrogens/Progestins
Therapeutics that treat disorders characterized by thinning of the vaginal walls with a combination of the female sex hormones estrogen and progestin.

Target Products:

  • Duramed Prefest (17-Estradiol/Norgestimate)
  
Oncology
Breast Cancer
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Methotrexate Sodium
  • Trexall (Methotrexate)
  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Target Products:

  • Tamoxifen Citrate
  
Progestins
Therapeutics that treat and manage breast cancers by providing progestins which in turn results in decreased estrogen levels.

Target Products:

  • Megestrol Acetate
  
Metastatic
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • TOCOSOL Paclitaxel (S-8184)
  
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.

Target Products:

  • Tamoxifen Citrate
  
Dermatology  
Malignant Melanoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancers of pigment cells in the epidermis and dermis by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Digestive System
Colon Cancer/Colorectal Cancer
Localized  
Vascular Endothelial Growth Factor Receptor Inhibitor (VEGFR)
Therapeutics that treat colorrectal cancer by binding specifically to the tyrosine kinase domain of vascular endothelial growth factor receptor (VEGFR) and inhibiting the formation of blood vessels around tumor cells.

Buyer Products:

  • Berlex PTK787 (Vatalanib)
  
Metastatic  
Vascular Endothelial Growth Factor Receptor Inhibitor (VEGFR)  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that treat colorectal cancers by helping to reduce toxicity by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Target Products:

  • Leucovorin
  
Head/Neck Cancer  
Localized  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by inhibiting the production of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Hematology
Leukemia
Lymphoid
Acute  
Lymphocytic  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Chronic  
Lymphocytic (CLL)  
Antimetabolite Agents  
Adenosine Deaminase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by inhibiting the transformation of deoxyadenosine into deoxyinosine thereby impairing DNA synthesis as well as leaving the cancer cells unable to repair single stranded DNA breaks.

Buyer Products:

  • Berlex Fludara (Fludarabine Phosphate)
  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.

Buyer Products:

  • Berlex Campath (Alemtuzumab)
  
Meningeal  
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage neoplasm's of immature immune cells that have spread to the brain by inhibiting an enzyme needed for the synthesis of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Myeloid  
Chronic  
Myelogenous (CML)  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Palliative Agents  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Lymphoma
Hodgkin`s Disease  
Palliative Agents  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphoma characterized by the presence of Reed-Sternberg cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Non-Hodgkin`s Lymphoma (NHL)
Antimetabolite Agents  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting the production of DNA.

Target Products:

  • Trexall (Methotrexate)
  • Methotrexate Sodium
  
Palliative Agents  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics that treat neutropenia and other cancer related conditions of lymphomas of B-cells and T-cells by inducing the maturation and proliferation of granulocytes, macrophages and mixed granulocyte-macrophage colonies of cells.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Musculoskeletal System
Bone Cancer  
Osteosarcoma  
Palliative Agents  
Folic Acid Derivatives
Therapeutics that are meant to reduce the toxicity of treating malignant tumors of the bone by allowing DNA/RNA/Protein synthesis to occur even when the pathway has been blocked by folic acid antagonists.

Target Products:

  • Leucovorin
  
Metastatic  
Osteolytic Bone Metastases  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat and manage bone cancers that have spread beyond their original tumor site by preventing the loss of bone mass followed by deposition of new bone which can result in entrapped tumors below the new bone surface.

Buyer Products:

  • Berlex Bonefos (Clodronate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • ZK-EPO (Epothilone)
  • Berlex MS-275 (Histone Deacytelators)
  • Oral Multi-target Tumor Growth Inhibitor (MTGI)
  • TOCOSOL Paclitaxel (S-8184)
  • Berlex PTK787 (Vatalanib)
  • Berlex MS209 (Multidrug Resistance Modulator)
  
Urology
Endometrial Cancer  
Localized  
Progestins
Therapeutics that treat and manage cancer of the endometrial cells lining the uterus by providing a female sex hormone necessary for the development of the female reproductive system.

Target Products:

  • Megestrol Acetate
  
Kidney Cancer (Renal Cell Carcinoma)  
Metastatic  
Hormonal Treatments  
Progestins
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by supplying a female sex hormone necessary for the development of the female reproductive system.

Target Products:

  • Megestrol Acetate
  
Ovarian Cancer  
Adenocarcinoma  
Ribonucleotide Reductase Inhibitors
Therapeutics that treat and manage cancer of cells lining the ovary by interfering with DNA synthesis.

Target Products:

  • Hydroxyurea
  
Prostate Cancer  
Localized  
Androgen Receptor Blockers
Therapeutics that treat prostate cancer by blocking androgen receptors. This limits the action of male hormones which have been implicated as a causative agent in prostate cancer.

Target Products:

  • CyPat (Cyproterone)
  
Metastatic  
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.

Target Products:

  • Flutamide
  
Uterine Cancer  
Uterine Fibroids (Leiomyoma, Uterus)  
Progestins Receptor Modulators
Therapeutics that treat and manage non-cancerous tumors of the uterus by modulating the effects of progesterone.

Buyer Products:

  • Berlex Asoprisnil
  
Ophthalmology  
Degenerative Disorders  
Glaucoma  
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.

Target Products:

  • Duramed Diamox (Acetazolamide)
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Target Products:

  • Diazepam
  
Narcotics  
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.

Target Products:

  • Oxycodone/Acetaminophen
  • Acetaminophen/Codeine
  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Meperidine Hydrochloride
  • Oral Transmucosal Fentanyl Citrate [C-II]
  
Non-Narcotics  
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.

Target Products:

  • Chlorzoxazone
  
Respiratory System
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Cathepsin S Inhibitor
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Target Products:

  • Fexofenadine Hydrochloride (12 Hours Extended Release)
  • Diphenhydramine Hydrochloride
  
Decongestants/Expectorants/Opioids
Therapeutics that treat coughs and colds by reducing mucous build up, suppressing coughs and help in ejection of mucous.

Target Products:

  • MedTuss HD Elixir C-III
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.

Target Products:

  • Triamcinolone Acetonide Nasal Spray
  
Surgery  
Cardiovascular System  
Thrombosis  
Thrombin Inhibitors
Therapeutics that thin the blood of a blocked blood vessel during surgery by blocking an enzyme involved in the clotting process.

Target Products:

  • Warfarin Sodium
  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Target Products:

  • Warfarin Sodium
  
Toxicology  
Substance Abuse  
Withdrawal  
Alcohol  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.

Target Products:

  • Diazepam
  • Chlordiazepoxide Hydrochloride
  
Opioid Antagonists
Therapeutics that treat alcohol dependence by blocking the effect of opioids.

Target Products:

  • Duramed ReVia (Naltrexone Hydrochloride)
  • Naltrexone Hydrochloride
  
Narcotics  
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.

Target Products:

  • Duramed ReVia (Naltrexone Hydrochloride)
  • Naltrexone Hydrochloride
  
Transplantation  
Bone Marrow  
Complications  
Neutropenia  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Peripheral Blood Progenitor Cell Transplant (PBPCT)  
Recovery  
Colony Stimulating Factors (CSF)  
Granulocyte Macrophage (rhGM-CSF)
Therapeutics containing biological proteins that stimulate the formation of certain white blood cell colonies.

Buyer Products:

  • Berlex Leukine (Sargramostim)
  
Urology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Progestogen Etonogestrel
  • Berlex Oxybutynin Releasing Vaginal Ring

Target Products:

  • Oxybutynin TVR
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Edema  
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.

Target Products:

  • Triamterene/Hydrochlorothiazide
  
Weight Management  
Anorexia (Appetite Loss)  
Progestins
Therapeutics that treat weight loss and other conditions arising from the uncontrolled loss of appetite by administration of hormone progestins.

Target Products:

  • Megestrol Acetate
  
Cachexia  
Anabolic Testosterone Analogs
Therapeutics containing a class of compounds that boost the body's metabolism and help in gaining weight.

Target Products:

  • Oxandrolone
  
Progestins
Therapeutics that treat cachexia by providing female hormones.

Target Products:

  • Megestrol Acetate
  
Medical Devices
Cardiology  
Diagnostic  
Imaging  
Magnetic Resonance Imaging (MRI)  
Contrast Agents
A drug that is introduced into a patient to attain better image quality.

Buyer Products:

  • Gadofluorine Derivative
  • Berlex Vasovist (Gadofosveset)
  
X-Ray  
Angiography  
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.

Buyer Products:

  • Medrad Mark V ProVis Injection System
  • Medrad Mark Series
  
Monitoring  
Monitors  
Vitals/Multiple Parameter  
Electrocardiogram (ECG/EKG)/Pulse Oximeter (SpO2)/ Multiple Vitals  
Portable
Device that measures, records, and displays the electrical signals of the heart, the oxygen concentration in the blood, the blood pressure with direct access to an artery and blood pressure with out direct access to an artery and can be moved around with the patient.

Buyer Products:

  • Medrad 9500 Vital Signs Patient Monitor
  
General Surgery  
Invasive  
Transplantation  
Organ Preservation
Devices used to preserve organs prior to transplantation.

Target Products:

  • ViaSpan (Belzer UW)
  
Neurology  
Surgical  
Region Specific  
Brain  
Stereotactic Surgery  
Guidance/ Planning Systems
Imaging equipment and/or computer systems that create a 3D map of the interior of the brain facilitating stereotactic surgery.

Buyer Products:

  • Medrad SimpliCT
  
Obstetrics/Gynecology  
Treatment  
Procedure Specific  
Contraception  
Intrauterine Devices (IUD)
IUDs, or Intrauterine devices, are a form of birth control used by women.

Target Products:

  • ParaGard T 380A
  
Oncology  
Diagnostic  
Imaging  
MRI  
Contrast Agents
A drug that is introduced into a patient to attain better MRI image quality.

Buyer Products:

  • Berlex Vasovist (Gadofosveset)
  
Radiology  
Computed Tomography (CT) Scan  
Accessories  
CT Contrast Injectors
Devices that mechanically push contrast agent into the patient.

Buyer Products:

  • Medrad EnVision CT
  • Medrad Stellant CT
  • Medrad Vistron CT
  
Syringes
Disposables used in contrast injection pumps.

Buyer Products:

  • Medrad Angiomat 3000/6000/6000CT
  • Medrad 100/200/300 Series
  • Medrad EnVision CT Front Load
  • Medrad MCT Plus Front Load
  • Medrad Viamonte-Hobbs 2000
  • Medrad Vistron CT Front Load
  
Contrast Agents  
Injectable
CT Scan contrast agents administered by injection.

Buyer Products:

  • Berlex Neotect (Kit for the Preparation of Technetium Tc 99m Depreotide Injection)
  • Berlex Acutect (Kit for the Preparation of Technetium Tc 99m Apcitide Injection)
  • Berlex Ultravist (Iopromide)
  
MRI  
Accessories  
Needle Systems
Injection systems used to deliver MRI contrast agents.

Buyer Products:

  • Medrad Spectris Solaris MR Injection Series
  • Medrad Continuum MR Compatible Infusion System
  • Medrad Spectris MR
  
Coils  
Closed MRI  
General Purpose
A closed MRI system that is designed to be used for multiple purpose imaging studies.

Buyer Products:

  • Medrad Multi-Purpose Array
  
Region Specific  
Abdominal
A coil that is placed on the abdomen to attain an image.

Buyer Products:

  • Medrad MRInnervu
  • Medrad Torso Array
  
Breast
A coil that is placed on the breast to attain an image of it.

Buyer Products:

  • Medrad Breast Coil/Array
  
Head/Neck
A coil that is placed on or around the head/neck to attain an image of it.

Buyer Products:

  • Medrad Neurovascular Array
  • Medrad Anterior Neck Coil
  
Lower Extremity
A coil that is placed on the lower extremity to attain an image of it.

Buyer Products:

  • Medrad Extremity Array
  
Spine
A coil that is placed near the spine to attain an image of it.

Buyer Products:

  • Medrad Quadrature Cervical Thoracic-Lumbar Array
  
Upper Extremity
A coil that is placed on an upper extremity to attain an image of it.

Buyer Products:

  • Medrad Extremity Array
  • Medrad Shoulder Coil
  
Vascular
A coil that is placed near a vessel to attain an image of it.

Buyer Products:

  • Medrad Gore Cardiovascular Array
  
Contrast Agents  
Injectable
A contrast agent that gets introduced to the body via a needle or IV.

Buyer Products:

  • Berlex Eovist
  • Berlex Magnevist (Gadopentetate Dimeglumine)
  • Berlex Feridex I.V. (Ferumoxide)
  • Berlex Vasovist (Gadofosveset)
  • Berlex SHU 555C
  • Berlex Primovist (Gadoxetic Acid)
  • Berlex Gadovist (Gadobutrol)
  • Berlex Resovist
  
Ultrasound  
Accessories  
Aspiration Needles
Biopsy needles that have special properties allowing ultrasound guidance.

Buyer Products:

  • Medrad Pulsar Injection System
  
X-Ray  
Contrast Agents  
Injectable
Introduced to the body via a needle.

Buyer Products:

  • Berlex Ultravist (Iopromide)
  • SF-64 (Omocianine)
  
Urology  
Diagnostic  
Imaging  
MRI  
Contrast Agents
A drug that is introduced into a patient to attain better MRI image quality.

Buyer Products:

  • Berlex Vasovist (Gadofosveset)
  
Vascular  
Diagnostic  
Imaging  
X-Ray  
Angiography  
Accessories
Various instruments used to assist in angiography procedures, including transducers, catheters, control syringes, waste systems, contrast management systems, fluid administration sets, and other related items.

Buyer Products:

  • Medrad Mark Series
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Roche Holding Ltd. (ADR) n/a 157,245.145 34.89 24.82 5.69 n/a 8.62
Teva Pharmaceutical Industries Ltd (ADR) n/a 25,046.770 64.06 14.03 3.33 2.95 34.79
Warner Chilcott Ltd. n/a 3,397.557 n/a 24.98 4.95 4.66 n/a
Noven Pharmaceuticals, Inc. n/a 548.127 36.71 35.39 9.10 9.20 3.43
Buyer
  Roche Holding Ltd. (ADR) n/a 157,245.145 34.89 24.82 5.69 n/a 8.62
Genentech, Inc. n/a 84,941.939 45.71 40.64 10.04 9.42 12.00
Target
  Johnson & Johnson n/a 190,922.506 17.25 17.85 3.65 3.63 7.01
Roche Holding Ltd. (ADR) n/a 157,245.145 34.89 24.82 5.69 n/a 8.62
Novartis AG (ADR) n/a 137,962.635 20.11 18.92 3.81 3.74 3.58
Wyeth n/a 64,708.887 15.89 15.26 3.26 3.22 6.16
Eli Lilly & Co. n/a 60,992.647 18.88 17.15 3.98 3.94 4.67
Bristol Myers Squibb Co. n/a 48,125.833 21.70 23.78 2.57 2.72 9.97
Teva Pharmaceutical Industries Ltd (ADR) n/a 25,046.770 64.06 14.03 3.33 2.95 34.79
Schering AG (ADR) n/a 22,955.147 30.48 n/a 3.27 n/a 6.62
Shire plc (ADR) n/a 10,059.401 36.11 35.11 5.70 5.62 11.70
Cephalon, Inc. n/a 4,565.708 27.21 17.42 2.83 2.70 n/a
Mylan Laboratories Inc. n/a 4,311.889 16.65 14.66 3.17 2.99 5.69
Warner Chilcott Ltd. n/a 3,397.557 n/a 24.98 4.95 4.66 n/a
Watson Pharmaceuticals, Inc. n/a 2,568.873 40.88 21.64 1.45 1.37 2.28
Dr. Reddy's Laboratories Limited (ADR) n/a 2,547.793 25.08 19.76 2.45 1.93 n/a
Perrigo Company n/a 1,585.788 21.04 19.58 1.14 1.10 4.61
Sciele Pharma Inc. n/a 814.257 18.26 19.63 2.90 2.83 12.82
Par Pharmaceutical Companies, Inc n/a 711.852 n/a 23.10 1.40 1.07 2.05
Momenta Pharmaceuticals, Inc. n/a 628.561 n/a -11.44 38.45 36.55 3.23
Noven Pharmaceuticals, Inc. n/a 548.127 36.71 35.39 9.10 9.20 3.43

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Advanced Magnetics, Inc. 47.00% 683.619 n/a -60.21 250.37 498.12 15.35
Biogen Idec Inc. n/a 17,365.400 105.62 24.29 6.66 6.52 5.90
Serono S.A. (ADR) n/a 13,657.170 19.97 19.08 4.99 4.87 5.65
Millennium Pharmaceuticals, Inc. n/a 3,612.192 n/a -286.50 7.70 7.57 6.47
Medarex, Inc. n/a 1,644.559 n/a -9.34 29.36 34.19 4.46
Crucell N.V. (ADR) n/a 1,397.634 n/a -13.44 14.23 7.49 3.80
Dendrite International, Inc. n/a 511.778 n/a 53.45 1.22 1.23 3.77
Penwest Pharmaceuticals n/a 422.847 n/a -13.24 114.56 110.91 8.71
OPNET Technologies, Inc. n/a 332.082 60.23 43.76 3.79 3.42 3.71
Peregrine Pharmaceuticals n/a 246.122 n/a n/a 72.26 n/a 8.49
EPIX Pharmaceuticals, Inc. n/a 125.667 n/a -2.99 20.31 15.99 n/a
Pharmacopeia Drug Discovery, Inc. n/a 85.337 n/a -2.54 4.44 4.80 4.51
Bioject Medical Technologies Inc. n/a 14.847 n/a n/a 1.55 n/a 2.54
Tripos, Inc. n/a 7.810 n/a n/a 0.18 n/a 0.38
Valentis, Inc. n/a 7.687 n/a n/a 10.58 n/a 3.16
Target
  Mack-Cali Realty Corp. n/a 3,428.858 38.25 14.73 4.87 4.83 2.31
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Millennium Pharmaceuticals, Inc. n/a 3,612.192 n/a -286.50 7.70 7.57 6.47
Cotherix, Inc n/a 384.762 n/a -14.06 6.41 5.57 4.49
Sonus Pharmaceuticals, Inc. n/a 213.430 n/a -7.65 8.62 8.95 4.34
Favrille, Inc. n/a 101.704 n/a -2.25 n/a n/a 1.89
Accentia Biopharmaceuticals, Inc n/a 100.865 n/a -2.34 3.72 3.31 n/a
Target
  McKesson Corporation 27.00% 14,259.786 17.26 17.85 0.16 0.15 3.50
Cardinal Health, Inc. 15.00% 25,195.796 24.17 16.98 0.30 0.28 7.48
AmerisourceBergen Corp. 11.00% 9,114.743 19.49 18.56 0.15 0.15 2.20
Walgreen Company 10.00% 40,773.890 23.29 20.62 0.86 0.76 4.03
KOS Pharmaceuticals, Inc. n/a 3,693.296 53.82 43.11 4.35 4.25 6.38
Warner Chilcott Ltd. n/a 3,397.557 n/a 24.98 4.95 4.66 n/a
Government - United States n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Warner Chilcott Ltd. n/a 3,397.557 n/a 24.98 4.95 4.66 n/a
Buyer
  Pfizer Inc. n/a 193,888.862 15.37 13.35 4.01 4.07 8.31
Novartis AG (ADR) n/a 137,962.635 20.11 18.92 3.81 3.74 3.58
AstraZeneca plc (ADR) n/a 89,001.730 15.25 14.69 3.48 3.38 8.92
Abbott Laboratories n/a 72,061.862 22.74 18.94 3.23 3.25 28.77
3M Company n/a 59,756.110 17.39 17.98 2.66 2.62 9.21
Koninklijke Philips Electronics NV (ADR) n/a 43,560.190 6.91 33.58 1.23 1.30 1.83
Biogen Idec Inc. n/a 17,365.400 105.62 24.29 6.66 6.52 5.90
Genzyme Corporation n/a 17,130.299 47.84 29.82 5.60 5.42 5.69
Serono S.A. (ADR) n/a 13,657.170 19.97 19.08 4.99 4.87 5.65
Vertex Pharmaceuticals Incorporated n/a 5,639.027 n/a -22.12 30.34 26.84 11.11
Millennium Pharmaceuticals, Inc. n/a 3,612.192 n/a -286.50 7.70 7.57 6.47
Warner Chilcott Ltd. n/a 3,397.557 n/a 24.98 4.95 4.66 n/a
Bausch & Lomb Inc. n/a 2,676.622 17.99 72.25 1.14 1.14 4.69
Target
  Teva Pharmaceutical Industries Ltd (ADR) n/a 25,046.770 64.06 14.03 3.33 2.95 34.79
Akzo Nobel N.V. (ADR) n/a 16,367.645 10.26 15.28 0.93 0.84 3.74
Shire plc (ADR) n/a 10,059.401 36.11 35.11 5.70 5.62 11.70
Cephalon, Inc. n/a 4,565.708 27.21 17.42 2.83 2.70 n/a
King Pharmaceuticals, Inc. n/a 4,023.575 25.56 9.76 2.12 2.05 3.35
KOS Pharmaceuticals, Inc. n/a 3,693.296 53.82 43.11 4.35 4.25 6.38
Warner Chilcott Ltd. n/a 3,397.557 n/a 24.98 4.95 4.66 n/a
Savient Pharmaceuticals, Inc. n/a 557.429 7.15 -533.50 8.90 7.94 3.05
Paladin Labs Inc. n/a 164.346 33.29 n/a 4.22 n/a 2.93
PLIVA d.d. n/a n/a n/a n/a n/a n/a n/a
Common Sense Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 7,009.5 1,202.4 8,211.9
Other Revenue 0.0 134.0 134.0
Total Revenue 7,009.5 1,336.4 8,345.9
Cost of Revenue 1,624.0 353.7 1,977.8
SG&A Expense 2,887.9 363.7 3,251.6
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 1,283.9 145.1 1,429.0
Interest Expense 0.0 0.0 0.0
Other Operating Expense 119.2 0.0 119.2
Total Expenses 5,915.1 862.5 6,777.6
Operating Income 1,094.4 473.9 1,568.3
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 18.8 20.6 39.4
Other, Net 28.9 -25.2 3.6
Income Before Taxes 1,142.1 469.2 1,611.3
Income Taxes 384.0 163.2 547.3
Income After Taxes 758.1 306.0 1,064.0
Minority Interest (IS) -5.0 0.0 -5.0
Net Income - Excl. Xord. Items 753.0 306.0 1,059.0
Net Income - Incl. Xord. Items 753.0 306.0 1,059.0
Income Avail. to Common 753.0 306.0 1,059.0
Share Items
Basic Avg. Shares Outstanding 192.4 106.3 298.7
Basic EPS - Excl. Xord. Items 3.91 2.88 3.55
Basic EPS - Incl. Xord. Items 3.91 2.88 3.55
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 192.4 108.1 300.5
F.D. EPS - Excl. Xord. Items 3.91 2.83 3.52
F.D. EPS - Incl. Xord. Items 3.91 2.83 3.52
Dividends Per Common Share 1.51 0.00 1.51
Balance Sheet
Assets
Cash and Equivalents 1,445.8 273.3 1,719.1
ST Investments 94.1 480.2 574.3
Accounts Receivable 1,865.0 212.9 2,077.9
Inventory 1,070.6 150.7 1,221.3
Prepayments and Advances 0.0 36.0 36.0
Other Current Assets 0.0 45.6 45.6
Current Assets 4,475.5 1,198.6 5,674.1
PPE 0.0 449.7 449.7
Accum D&A 0.0 -172.2 -172.2
PPE, Net 1,408.2 277.5 1,685.7
Goodwill & Intangibles 829.6 520.3 1,349.9
Long Term Investments 268.6 14.0 282.6
Other Assets 0.0 0.0 0.0
Other LT Assets 396.6 58.1 454.7
Total Assets 7,378.4 2,068.4 9,446.9
Liabilities
Accounts Payable 0.0 82.6 82.6
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 0.0 104.2 104.2
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 30.1 8.5 38.6
Other (Current) Liabilities 1,907.7 40.8 1,948.5
Current Liab. 1,937.8 236.1 2,173.9
LT Debt 268.6 7.4 276.0
Total LT Debt 268.6 7.4 276.0
Minority Interest (BS) 23.8 0.0 23.8
Other LT Liab. 850.9 60.9 911.8
Total Liabilities 3,081.2 304.4 3,385.6
Shareholders Equity
Common Stock 243.5 1.1 244.6
Additional Paid in Capital 419.2 594.9 1,014.0
Retained Earnings 3,638.4 1,268.9 4,907.3
Treasure Stock -3.8 -100.7 -104.5
Other Equity 0.0 -0.2 -0.2
Total Equity 4,297.3 1,764.0 6,061.3
Total Liab. & Equity 7,378.4 2,068.4 9,446.9
Shares Outstanding 190.8 106.4 297.2
Cash Flow
Operating Cash Flow
CF Net Income 758.1 211.1 969.2
CF Depreciation 430.5 54.6 485.1
CF Deferred Taxes 0.0 -12.7 -12.7
Other Non-Cash Items -86.6 41.5 -45.1
Change in Working Capital 356.4 133.6 490.0
Total Cash From Operating Activities 1,458.4 428.0 1,886.4
Investing Cash Flow (not calculated)
Capital Expenditures -377.8 -99.3 -477.1
Other Investing Cash Flows -7.5 -123.4 -130.9
Total Cash From Investing Activities -385.3 -222.7 -608.0
Financing Cash Flow (not calculated)
Dividends Paid -291.2 0.0 -291.2
Purchase Or Sale of Stock 74.0 26.3 100.3
Purchase and Retirement of Debt 0.0 -1.1 -1.1
Other Financing Cash Flow -579.8 12.7 -567.1
Total Cash From Financing Activities -797.0 37.9 -759.1
Exchange Rate Effects -12.6 0.0 -12.6
Net Change in Cash 263.6 243.2 506.8
Cash Taxes Paid 252.3 130.2 382.5
Cash Interest Paid 15.1 0.5 15.5